Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases

被引:38
作者
Liu, Yulong [1 ,2 ]
Shields, Lisa B. E. [3 ]
Gao, Zhongwen [1 ,2 ]
Wang, Yuanyi [2 ,4 ]
Zhang, Yi Ping [3 ]
Chu, Tianci [2 ]
Zhu, Qingsan [1 ]
Shields, Christopher B. [3 ]
Cai, Jun [2 ]
机构
[1] Jilin Univ, China Japan Union Hosp, Dept Orthoped Surg, Changchun 130033, Peoples R China
[2] Univ Louisville, Sch Med, Dept Pediat, 570 S Preston St,Donald Baxter Bldg,Suite 321B, Louisville, KY 40202 USA
[3] Norton Healthcare, Norton Neurosci Inst, Norton, KY 40202 USA
[4] Jilin Univ, Hosp 1, Dept Spine Surg, Changchun 130021, Peoples R China
关键词
Platelet-activating factor; Receptor; Diseases; Central nervous system; SPINAL-CORD-INJURY; TUMOR-NECROSIS-FACTOR; FACTOR PAF RECEPTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; FACTOR-KAPPA-B; GINKGOLIDE-B; RAT-BRAIN; MULTIPLE-SCLEROSIS; NEURONAL APOPTOSIS; PHOSPHOLIPASE A(2);
D O I
10.1007/s12035-016-0062-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Platelet-activating factor (PAF) is a bioactive lipid mediator which serves as a reciprocal messenger between the immune and nervous systems. PAF, a pluripotent inflammatory mediator, is extensively expressed in many cells and tissues and has either beneficial or detrimental effects on the progress of inflammation-related neuropathology. Its wide distribution and various biological functions initiate a cascade of physiological or pathophysiological responses during development or diseases. Current evidence indicates that excess PAF accumulation in CNS diseases exacerbates the inflammatory response and pathological consequences, while application of PAF inhibitors or PAFR antagonists by blocking this signaling pathway significantly reduces inflammation, protects cells, and improves the recovery of neural functions. In this review, we integrate the current findings of PAF signaling in CNS diseases and elucidate topics less appreciated but important on the role of PAF signaling in neurological diseases. We propose that the precise use of PAF inhibitors or PAFR antagonists that target the specific neural cells during the appropriate temporal window may constitute a potential therapy for CNS diseases.
引用
收藏
页码:5563 / 5572
页数:10
相关论文
共 124 条
  • [1] Platelet-Activating Factor: a Role in Preterm Delivery and an Essential Interaction with Toll-Like Receptor Signaling in Mice
    Agrawal, Varkha
    Jaiswal, Mukesh Kumar
    Ilievski, Vladimir
    Beaman, Kenneth D.
    Jilling, Tamas
    Hirsch, Emmet
    [J]. BIOLOGY OF REPRODUCTION, 2014, 91 (05)
  • [2] Interaction between neurone and microglia mediated by platelet-activating factor
    Aihara, N
    Ishii, S
    Kume, K
    Shimizu, T
    [J]. GENES TO CELLS, 2000, 5 (05) : 397 - 406
  • [3] Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells
    Akai, T
    Niiya, K
    Sakuragawa, N
    Iizuka, H
    Endo, S
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (03) : 193 - 198
  • [4] Differential regulation of formyl peptide and platelet-activating factor receptors -: Role of phospholipase Cβ3 phosphorylation by protein kinase A
    Ali, H
    Sozzani, S
    Fisher, I
    Barr, AJ
    Richardson, RM
    Haribabu, B
    Snyderman, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) : 11012 - 11016
  • [5] Platelet-activating factor induces nitric oxide synthesis in Trypanosoma cruzi-infected macrophages and mediates resistance to parasite infection in mice
    Aliberti, JCS
    Machado, FS
    Gazzinelli, RT
    Teixeira, MM
    Silva, JS
    [J]. INFECTION AND IMMUNITY, 1999, 67 (06) : 2810 - 2814
  • [6] How should we proceed with disease-modifying treatments for multiple sclerosis?
    Andersson, PB
    Waubant, E
    Goodkin, DE
    [J]. LANCET, 1997, 349 (9052) : 586 - 587
  • [7] Platelet-activating factor acetylhydrolase (PAF-AH)
    Arai, H
    Koizumi, H
    Aoki, J
    Inoue, K
    [J]. JOURNAL OF BIOCHEMISTRY, 2002, 131 (05) : 635 - 640
  • [8] Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury
    Azbill, RD
    Mu, XJ
    BruceKeller, AJ
    Mattson, MP
    Springer, JE
    [J]. BRAIN RESEARCH, 1997, 765 (02) : 283 - 290
  • [9] Bacchetti T, 2015, HIGHER LEVELS OXIDIZ, P1875
  • [10] BALENTINE JD, 1978, LAB INVEST, V39, P236